Your AI-Trained Oncology Knowledge Connection!
Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc; Richardo D. Parrondo, MD; Nicole Lamanna, MD, and Alexey Danilov, MD, PhD, examine treatment approaches for newly diagnosed chronic lymphocytic leukemia (CLL), including BTK inhibitor therapy, management of adverse events, and strategies for relapsed/refractory CLL.
Five medical provide insights around breakthrough treatment strategies in relapsed/recurrent DLBCL.
John Marshall, MD; Al B. Benson III, MD, FACP, FACCC, FASCO; Kristen Ciombor, MD, MSCI; Stacey Cohen, MD, and Marwan Fakih, MD, examine the landscape of second-line and third-line treatments for metastatic colorectal cancer, along with recent advancements in managing the disease.
Vijayakrishna Gadi, MD, PhD, sets the stage for a discussion around HER2-directed ADCs in the solid tumor space.
Led by Sandip P. Patel, MD, key opinion leaders address key updates in treatment strategies and management of stage III NSCLC.
Guillermo Garcia-Manero, MD; Rami Komrokji, MD; Esther Natalie Oliva, MD; Amer Zeidan, MBBS, MHS, and Dr Thomas Cluzeauprovide expert insights on the latest developments in Lower-Risk Myelodysplastic Syndromes (LR-MDS) as presented at the European Hematology Association (EHA) 2024 conference.
Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.
A panel of medical experts reviews the latest advances in managing and treating renal cell carcinoma (RCC) and non-clear cell renal cell carcinoma (nccRCC), discussing recent trial data and sharing insights from their clinical practices.
Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD, and Benjamin Levy, MD,discuss the current standard of care, emerging data on novel therapies such as antibody-drug conjugates (ADCs) and clinical trials, patient selection considerations, and practical guidance foroptimizing patient care.
Kelly McCann, MD, PhD, drives a discussion surrounding key topics and highlights in HR+ breast cancer treatment as presented at ASCO 2024.
A panel of experts on HER2+ breast cancer has a comprehensive discussion on recent data updates and how they might impact clinical practice.
Lori Wirth, MD, moderates a panel of medical experts specializing in radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), discussing current treatments and ongoing clinical trials in this field.
A panel of experts on colorectal cancer provides comprehensive insights on MRD testing within the disease space, highlight the general landscape, recent data, ongoing trials, and future directions.
A panel of thoracic oncologists have a comprehensive discussion on the treatment of HER2 non–small cell lung cancer, covering diagnosis, therapies, clinical trials, and unmet needs in the treatment space.
Following ASCO GU 2024, a panel of GU medical oncologists discuss recent updates in bladder cancer and provide comprehensive insights on the evolving treatment landscape.
Aparna Parikh, MD, leads a panel discussion surrounding updates and advancements in the metastatic colorectal cancer treatment landscape.
A panel of medical oncologists specializing in the treatment of renal cell carcinoma have a comprehensive discussion on updates in the treatment of advanced RCC following ASCO GU 2024.
A panel of medical experts discuss key highlights from ASCO GI 2024 surrounding the hepatocellular carcinoma (HCC) treatment landscape.
Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss current and emerging treatment landscape of chronic graft-versus-host disease (GVHD). They examine treatment selection in different lines of therapies and the near future landscape of treatment when newer mechanisms of action become available for GVHD.
A panel of experts discuss recent data updates on the treatment and management of HER2+ breast cancer and how these data may impact practice.
A panel of hematologist-oncologists provides an overview of the diagnosis and treatment of myelodysplastic syndromes (MDS) and offers comprehensive insights on the evolving treatment landscape.
A team of expert oncologists delves into the latest developments in treating AL amyloidosis, placing particular emphasis on innovative therapies aimed at targeting amyloid deposits.
A panel of experts discuss recent updates including new data from ASH 2023 on the treatment of follicular lymphoma and mantle cell lymphoma as well as their clinical implications.
Experts discuss several recent data updates in polycythemia vera and myelofibrosis in the context of the treatment landscape and its impact on clinical practice.
A panel of expert oncologists explore advancements in the treatment of CLL, reviewing recent data updates from ASH 2023 and their potential impact on clinical practice.
A panel of expert oncologists explore recent advancements in the treatment of desmoid tumors, highlighting the approval of nirogacestat as the first FDA-approved in this treatment setting, and discussing its impact on clinical practice.
